Today: 10 June 2026
Browse Category

NYSE:PFE 30 December 2025 - 12 January 2026

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI shares rose about 11% in premarket trading Monday after the company reported preliminary 2025 revenue of $1.27 billion, up 83% year-on-year, and record contract value exceeding $1.1 billion. The company cited strong growth in both Diagnostics and Data segments, with over 70 new data agreements signed in 2025. Tempus noted the results are unaudited and subject to change.
12 January 2026
·······
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer shares rose 0.3% to $25.36 after a U.S. appeals court blocked a Trump-era pilot that would have changed drug payments for safety-net hospitals. The ruling affects drugs like Eliquis, co-marketed by Pfizer and Bristol Myers Squibb. Investors await Pfizer CEO Albert Bourla’s update at the J.P. Morgan Healthcare Conference on Jan. 12. Pfizer reports earnings Feb. 3, with COVID sales and patent losses in focus.
8 January 2026
··
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer shares closed up 1.1% at $25.18 on Friday, after leading U.S. drugmakers in January list-price hikes, including a 15% increase for its COVID vaccine Comirnaty. The stock remains below its 52-week high of $27.69. Investors await Pfizer’s Feb. 3 earnings update and monitor upcoming U.S. jobs and inflation data.
3 January 2026
····
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

U.S. drugmakers are raising list prices on at least 350 branded medicines for 2026, with a median increase of about 4%, Reuters reported. The Health Care Select Sector SPDR Fund (XLV) closed up 0.46% at $155.51 Friday. Pfizer, Eli Lilly, and Johnson & Johnson all posted gains. Traders are watching next week’s U.S. jobs data and upcoming healthcare earnings.
3 January 2026
····
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson closed Friday up 0.19% at $207.35 after declaring a $1.30-per-share quarterly dividend, payable March 10 to shareholders of record as of Feb. 24. The stock traded between $203.68 and $207.37 during the session. Investors await J&J’s Jan. 21 earnings call and next week’s U.S. labor data. The S&P 500 finished up 0.19%.
3 January 2026
·····
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer shares rose 0.8% to $25.09 Friday amid renewed focus on U.S. drug pricing after reports of 2026 list-price hikes, including a 15% increase for its COVID-19 vaccine. A Reuters report said Pfizer will lead price increases on about 80 drugs, though most hikes are under 10%. Investors await Pfizer’s next quarterly update on February 3. Trading volume reached about 20.7 million shares.
2 January 2026
··
Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

Pfizer shares fell 0.4% to $24.90 in premarket trading Friday after Reuters reported the company plans to raise U.S. list prices on about 80 medicines in 2026, including a 15% hike for COVID-19 vaccine Comirnaty. The moves come as drugmakers face pressure from the Trump administration to lower prices and as investors await Pfizer’s February 3 results update.
2 January 2026
··
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer shares slipped 0.4% to $24.90 after hours following a report the company will raise U.S. list prices on about 80 medicines in 2026, including a 15% hike for its COVID vaccine Comirnaty. Most Pfizer increases are under 10%. U.S. stock markets were closed Thursday for New Year’s Day. Investors await Pfizer’s Feb. 3 results and 2026 outlook.
1 January 2026
···
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer shares fell 0.4% to $24.90 in after-hours trading after reports the company will lead U.S. drug list-price increases in 2026, including a 15% hike for its COVID vaccine. Healthcare data show Pfizer plans about 80 price increases, as drugmakers prepare for the annual January price reset under political scrutiny. Investors await further pricing updates and Pfizer’s February earnings call.
1 January 2026
···
Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer shares slipped 0.02% to $24.99 in late after-hours trading Tuesday. TD Cowen reiterated a Hold rating and $30 price target, citing weak longer-term trends. Investors await Pfizer’s next results for signs it can offset declining COVID sales and upcoming patent expirations. Pfizer forecasts 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00.
31 December 2025
···
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer shares edged up 0.1% to $25.03 Tuesday after TD Cowen reiterated a Hold rating and $30 price target, citing negative trends through 2030. The company projected 2026 revenue of $59.5 billion to $62.5 billion and warned of a “bumpy” period ahead as COVID demand fades and key patents expire. Shares have dropped over 50% since early 2023. Pfizer’s next earnings report is set for February 3.
30 December 2025
··
1 2 3 4 5 6 … 10

Stock Market Today

  • Middle East Tensions and EIA Report Lift Crude Oil Prices
    June 10, 2026, 1:48 PM EDT. Crude oil prices rose sharply following escalated hostilities between the US and Iran near the Strait of Hormuz and a bullish US Energy Information Administration (EIA) inventory report. July WTI crude gained 1.51% and July RBOB gasoline climbed 2.01%. Military strikes and missile launches heightened supply disruption concerns. However, lower Chinese crude imports and forecasts of increased US production weighed on prices. The International Energy Agency (IEA) warned of a severely undersupplied oil market through October. Additional pressure came from restricted Russian outputs due to drone attacks and sanctions. Meanwhile, OPEC intends to raise production quotas, potentially easing supply tightness by September.

Latest articles

MARA Shares Drop as Miner Selloff Hits Bitcoin-Linked Stocks

MARA Shares Drop as Miner Selloff Hits Bitcoin-Linked Stocks

10 June 2026
MARA Holdings shares slid 3.9% to $12.79, underperforming Bitcoin’s rebound above $62,000, as investors repriced crypto miners amid tech stock weakness, high energy costs, and sector-wide pressure; MARA’s future now hinges on its pivot toward power infrastructure and AI, with its $1.5B Long Ridge Energy deal pending regulatory approval and Bitcoin price swings still driving revenue and massive quarterly losses.
UiPath Stock Moves Higher, but ARR Growth Stays in Focus for PATH

UiPath Stock Moves Higher, but ARR Growth Stays in Focus for PATH

10 June 2026
UiPath shares edged up 1% to $10.87 after Tuesday’s 3.76% drop, as investors focus on slowing ARR growth; the company guided Q2 ARR to $1.929–$1.934 billion, below last quarter’s $49 million net new ARR, leaving Wall Street cautious despite first-ever GAAP profitability and a new $500 million buyback.
BigBear.ai Stock Bounces as Shareholder Vote Squeeze Meets Panama AI Speculation

BigBear.ai Stock Bounces as Shareholder Vote Squeeze Meets Panama AI Speculation

10 June 2026
BigBear.ai shares rose 2.8% to $4.10 as investors weighed the approved move to double authorized shares to 1 billion, giving the company flexibility for financing but raising dilution risks, while the Panama cargo-security rollout and $281.9 million backlog keep growth hopes alive amid ongoing losses and revenue conversion questions.
Go toTop